These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8093845)

  • 1. Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex.
    Beltangady M; Knupp CA; Gustafson N; Barbhaiya RH; Dolin R; Seidlin M; Cooley TP; Rozencweig M
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S26-31. PubMed ID: 8093845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC; Martin ES
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Didanosine: long-term follow-up of patients in a phase 1 study.
    Lambert JS; Seidlin M; Valentine FT; Reichman RC; Dolin R
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S40-5. PubMed ID: 8093846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.
    Nguyen BY; Shay LE; Wyvill KM; Pluda JM; Brawley O; Cohen RB; Whitcup SM; Venzon DJ; Broder S; Yarchoan R
    J Infect Dis; 1993 Oct; 168(4):810-7. PubMed ID: 8397267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.
    Yarchoan R; Mitsuya H; Pluda JM; Marczyk KS; Thomas RV; Hartman NR; Brouwers P; Perno CF; Allain JP; Johns DG
    Rev Infect Dis; 1990; 12 Suppl 5():S522-33. PubMed ID: 1974724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
    Kahn JO; Lagakos SW; Richman DD; Cross A; Pettinelli C; Liou SH; Brown M; Volberding PA; Crumpacker CS; Beall G
    N Engl J Med; 1992 Aug; 327(9):581-7. PubMed ID: 1353607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Didanosine in the treatment of AIDS and AIDS-related complex: a critical appraisal of the dose and frequency of administration.
    Liebman HA; Cooley TP
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S52-8. PubMed ID: 8093847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial.
    Drusano GL; Yuen GJ; Lambert JS; Seidlin M; Dolin R; Valentine FT
    Ann Intern Med; 1992 Apr; 116(7):562-6. PubMed ID: 1347442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
    Cooley TP; Kunches LM; Saunders CA; Perkins CJ; Kelley SL; McLaren C; McCaffrey RP; Liebman HA
    Rev Infect Dis; 1990; 12 Suppl 5():S552-60. PubMed ID: 1974727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
    Reichman RC; Tejani N; Lambert JL; Strussenberg J; Bonnez W; Blumberg B; Epstein L; Dolin R
    Antiviral Res; 1993 Apr; 20(4):267-77. PubMed ID: 8097906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.
    Knupp CA; Shyu WC; Dolin R; Valentine FT; McLaren C; Martin RR; Pittman KA; Barbhaiya RH
    Clin Pharmacol Ther; 1991 May; 49(5):523-35. PubMed ID: 1903100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
    Cooley TP; Kunches LM; Saunders CA; Ritter JK; Perkins CJ; McLaren C; McCaffrey RP; Liebman HA
    N Engl J Med; 1990 May; 322(19):1340-5. PubMed ID: 2139174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
    Spruance SL; Pavia AT; Peterson D; Berry A; Pollard R; Patterson TF; Frank I; Remick SC; Thompson M; MacArthur RD; Morey GE; Ramirez-Ronda CH; Bernstein BM; Sweet DE; Crane L; Peterson EA; Pachucki CT; Green SL; Brand J; Rios A; Dunkle LM; Cross A; Brown MJ; Ingraham P; Gugliotti R; Schindzielorz AH; Smaldone L
    Ann Intern Med; 1994 Mar; 120(5):360-8. PubMed ID: 7905722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex.
    Pai SM; Shukla UA; Grasela TH; Knupp CA; Dolin R; Valentine FT; McLaren C; Liebman HA; Martin RR; Pittman KA
    J Clin Pharmacol; 1992 Mar; 32(3):242-7. PubMed ID: 1564128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex.
    Dolin R; Lambert JS; Morse GD; Reichman RC; Plank CS; Reid J; Knupp C; McLaren C; Pettinelli C
    Rev Infect Dis; 1990; 12 Suppl 5():S540-9; discussion S549-51. PubMed ID: 1974726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
    N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.
    Skowron G; Bozzette SA; Lim L; Pettinelli CB; Schaumburg HH; Arezzo J; Fischl MA; Powderly WG; Gocke DJ; Richman DD; Pottage JC; Antoniskis D; McKinley GF; Hyslop NE; Ray G; Simon G; Reed N; LoFaro ML; Uttamchandani RB; Gelb LD; Sperber SJ; Murphy RL; Leedom JM; Grieco MH; Zachary J; Hirsch MS; Spector SA; Bigley J; Soo W; Merigan TC
    Ann Intern Med; 1993 Mar; 118(5):321-30. PubMed ID: 8094279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI).
    Reddy MM; McKinley GF; Grieco MH
    J Clin Lab Anal; 1991; 5(6):396-8. PubMed ID: 1774603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.